Allergy Therapeutics (LON:AGY) Trading Up 2.2% – Here’s Why

Shares of Allergy Therapeutics plc (LON:AGY) traded up 2.2% during trading on Tuesday . The company traded as high as GBX 6.50 ($0.08) and last traded at GBX 5.93 ($0.07). 318,980 shares changed hands during trading, a decline of 42% from the average session volume of 551,773 shares. The stock had previously closed at GBX 5.80 ($0.07).

Allergy Therapeutics Stock Up 12.1 %

The stock’s fifty day moving average is GBX 6.54 and its two-hundred day moving average is GBX 5.42. The company has a current ratio of 1.40, a quick ratio of 1.48 and a debt-to-equity ratio of 37.22. The company has a market capitalization of £310.05 million, a PE ratio of -108.33, a P/E/G ratio of -30.70 and a beta of 1.40.

Allergy Therapeutics (LON:AGY) last posted its quarterly earnings data on Wednesday, November 6th. The company reported GBX (1.07) (($0.01)) earnings per share for the quarter. Allergy Therapeutics had a negative return on equity of 155.90% and a negative net margin of 94.29%. As a group, analysts predict that Allergy Therapeutics plc will post -2.56 EPS for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.